80042105 - Third Annual Lung Cancer Update - Advances in Screening, Diagnostics and Therapeutics

Third Annual Lung Cancer Update - Advances in Screening, Diagnostics and Therapeutics Banner


Date & Location
Friday, April 13, 2018 7:00 AM - 5:00 PM   The Friday Center, Chapel Hill, NC

Target Audience
Critical Care Medicine, Oncology, Pulmonary Disease

Overview

Lung cancer is the leading cause of cancer death in the United States, with an estimated 220,000 new diagnoses of lung cancer in 2016 resulting in an estimated 150,000 deaths, making lung cancer more deadly than breast, prostate and colon cancer combined. Although the number of new cases of lung cancer is declining, the death rates continues to be a staggering one. Among new diagnoses in the United States, approximately 40% occur in current smokers, 40% in former smokers, and 20% in patients who have never smoked. Difficulties faced in the treatment of lung cancer are compounded by the frequent late stage of diagnosis in combination with associated environmental and genetic factors.


Recent advances in lung cancer research have provided improved understanding and stratification of different types of non-small-cell lung cancer. This has led to a further research which has and continues to identify targetable molecular and genetic mutations. As our knowledge improves, the previous practice to treat all non-smallcell lung cancer with cytotoxic chemotherapeutic agents has undergone immense change. We are now entering an era of personalized therapy in which lung cancer is characterized by specific potentially targetable genetic alterations. Recognizing these targets, developing and testing targeted chemotherapeutics and evaluating mechanisms of tumor resistance require a multi-disciplinary approach and collaborative efforts. In addition, understanding best practices in tissue acquisition and processing is of utmost importance.



Objectives
  1. Describe the appropriate selection of diagnostic modalities in the work-up of a patient with suspected lung cancer.
  2. Identify and describe updates and advances in chemotherapy treatment for patients with advanced lung cancer.
  3. Discuss new advances in immunotherapy in the treatment of lung cancer.
  4. Evaluate patients with malignant airway obstruction, mediastinal/hilar lymph adenopathy and peripheral lung lesions.
  5. Evaluate patients with newly diagnosed lung nodules.
  6. Discuss novel non-invasive detection of lung cancer.
  7. Discuss the side effects associated with new chemotherapeutic agents and their management.

Accreditation

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.


CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other Credits
American Academy of Nurse Practitioners National Certification Program (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 7.5 AAPA Category 1 CME credits for completing this program. Application has been made to the American Association for Respiratory Care (AARC) for continuing education contact hours for respiratory therapists.

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

The Johns Hopkins University has approved this activity for 7.5 contact hours for non-physicians.